HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Hangzhou Tigermed Consulting (3347.HK/300347.CH) - More of an Investment Company than a CRO

Wuxi Biologics (2269.HK) 2021Q3 - The Strength and the Concerns Behind the New Full-Year Guidance

Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns

WuXi Biologics (2269 HK) - The Strength and the Potential Risk

Asymchem Laboratories (002821.CH) 2021H1 Results - Not Good Enough

WuXi AppTec (603259.CH/2359.HK) - The Smart Business Model

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Bottom-Up

<p>In October 2021, <a href="https://www.smartkarma.com/entities/pharmaron-beijing-co-ltd" target="_blank" data-smartkarma-citation="entities:28428:1" rel="noopener">Pharmaron Beijing Co Ltd-H (3759 HK) </a>completed the new investment in Zhongke Lingrui (Zhanjiang) Biotechnology. In the CRO industry, companies such as <a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec Co. Ltd. (2359 HK)</a>, Pharmaron, <a href="https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-co-ltd-1008d609-73bd-4d76-8315-b29502a448ff" target="_blank" data-smartkarma-citation="entities:29212:1" rel="noopener">Hangzhou Tigermed Consulting (H) (3347 HK) </a>and others are all on the hunt for acquisitions. However, investors seems to be more interested in when Pharmaron would truly achieve " integration". On the other hand, Pharmaron just released its 2021Q3 results. The revenue was RMB5.3 billion, up 47.84% YoY, and the net profit was RMB1 billion, up 31.02% YoY. This insight mainly analyzed the business and the concerns of the Company when it is compared with WuXi AppTec.</p>

In October 2021, Pharmaron Beijing Co Ltd-H (3759 HK) completed the new investment in Zhongke Lingrui (Zhanjiang) Biotechnology. In the CRO industry, companies such as WuXi AppTec Co. Ltd. (2359 HK), Pharmaron, Hangzhou Tigermed Consulting (H) (3347 HK) and others are all on the hunt for acquisitions. However, investors seems to be more interested in when Pharmaron would truly achieve " integration". On the other hand, Pharmaron just released its 2021Q3 results. The revenue was RMB5.3 billion, up 47.84% YoY, and the net profit was RMB1 billion, up 31.02% YoY. This insight mainly analyzed the business and the concerns of the Company when it is compared with WuXi AppTec.

Pharmaron Beijing Co Ltd (3759.HK) 2021Q3 - Still Takes Time to Challenge Wuxi AppTec